Craig Hallum Increases Zoetis (NYSE:ZTS) Price Target to $138.00
Zoetis (NYSE:ZTS) had its target price boosted by Craig Hallum from $132.00 to $138.00 in a report published on Wednesday morning, The Fly reports. They currently have a buy rating on the stock.
Other equities research analysts have also issued research reports about the company. Stifel Nicolaus upped their price target on Zoetis from $110.00 to $130.00 and gave the company a buy rating in a research report on Monday, July 22nd. Bank of America downgraded Zoetis from a buy rating to a neutral rating and boosted their price objective for the company from $111.00 to $120.00 in a research note on Monday, July 1st. They noted that the move was a valuation call. Cantor Fitzgerald reissued an overweight rating and issued a $130.00 price objective (up from $116.00) on shares of Zoetis in a research note on Wednesday, June 12th. BMO Capital Markets boosted their price objective on Zoetis from $101.00 to $105.00 and gave the company a market perform rating in a research note on Thursday, May 9th. Finally, Gabelli downgraded Zoetis from a buy rating to a hold rating and set a $108.00 price objective on the stock. in a research note on Thursday, May 2nd. They noted that the move was a valuation call. Seven investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Zoetis presently has a consensus rating of Buy and a consensus target price of $113.13.
NYSE ZTS opened at $125.07 on Wednesday. The company has a 50-day moving average of $115.02. Zoetis has a 12 month low of $78.90 and a 12 month high of $125.88. The company has a market cap of $57.86 billion, a price-to-earnings ratio of 39.96, a PEG ratio of 3.21 and a beta of 0.92. The company has a debt-to-equity ratio of 2.74, a current ratio of 4.17 and a quick ratio of 2.79.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 19th will be paid a $0.164 dividend. This represents a $0.66 dividend on an annualized basis and a dividend yield of 0.52%. The ex-dividend date of this dividend is Thursday, July 18th. Zoetis’s dividend payout ratio is 21.09%.
In related news, Director Willie M. Reed sold 1,900 shares of the company’s stock in a transaction that occurred on Thursday, June 13th. The stock was sold at an average price of $110.58, for a total transaction of $210,102.00. Following the transaction, the director now directly owns 2,816 shares of the company’s stock, valued at approximately $311,393.28. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Glenn David sold 8,191 shares of the company’s stock in a transaction that occurred on Friday, May 17th. The stock was sold at an average price of $102.22, for a total value of $837,284.02. The disclosure for this sale can be found here. Insiders sold a total of 47,160 shares of company stock worth $4,969,469 over the last three months. 0.29% of the stock is owned by company insiders.
A number of hedge funds have recently bought and sold shares of ZTS. JJJ Advisors Inc. purchased a new stake in shares of Zoetis in the second quarter worth approximately $25,000. Farmers & Merchants Trust Co of Chambersburg PA purchased a new stake in shares of Zoetis in the first quarter worth approximately $25,000. Glassman Wealth Services raised its stake in shares of Zoetis by 306.5% in the first quarter. Glassman Wealth Services now owns 252 shares of the company’s stock worth $25,000 after purchasing an additional 190 shares during the last quarter. Altshuler Shaham Ltd raised its stake in shares of Zoetis by 198.8% in the second quarter. Altshuler Shaham Ltd now owns 254 shares of the company’s stock worth $29,000 after purchasing an additional 169 shares during the last quarter. Finally, Private Ocean LLC purchased a new stake in shares of Zoetis in the first quarter worth approximately $27,000. 90.12% of the stock is currently owned by institutional investors and hedge funds.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Article: Discover Your Risk Tolerance
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.